10 April 2024 — Manchester, UK — Following its recent clinical trial partnership announcement, Pill Connect the smart dosing device company, has chosen Aptar Digital Health as its first collaboration in the SAMD (Software as a Medical Device) and digital solutions market.
Pill Connect’s ambition in SaMD is to enhance the ability of digital analysis by providing more accurate data, without burdening the patient. It is expected that combining accurate dosing data with outcomes, such as biomarkers and patient feedback assessments, will lead to more personalised dosing regimens, where outcomes can be reached with fewer side effects. The aim is to safely calculate, then administer unique dosing regimens developed for each patient based on their real-life data.
Providing an accurate, yet low burden, remote digital care plan is becoming important when supporting the movement of treatment from Hospital to Home care. In critical medicines with complex dosing regimens, adherence monitoring and accountability will be pivotal to ensuring treatment success.
“It’s unlikely that one dose fits all! By combining with powerful platforms such as Aptar Digital Health, we can build an end-to-end product monitoring and analysing each patient’s unique responses to dosing. We want to investigate whether personalised adjustments to dosing can improving quality of life whilst still resulting in the treatment aims.” said James Burnstone, CEO at Pill Connect. “We are gaining real traction and are delighted with the strength of our new business pipeline. Working with a global leader such as Aptar Pharma reinforces the positive direction of travel for our technology, which, as the only platform agnostic device, is now validated and ready to use in both commercial trials and marketed therapies.”